Trial Profile

A Phase I Clinical Trial of T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti SLAMF7 chimeric antigen receptor T cell therapy (Primary) ; Cyclophosphamide; Fludarabine; Rimiducid
Indications Multiple myeloma; Plasmacytoma
Focus Adverse reactions

Most Recent Events

20 Jan 2021 Status changed from recruiting to completed.
20 Jun 2020 Planned number of patients changed from 42 to 36.
25 Jun 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 27 Jun 2019 to 1 Jul 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com